Favorable Press Coverage Somewhat Unlikely to Impact Xenon Pharmaceuticals (XENE) Share Price

Media stories about Xenon Pharmaceuticals (NASDAQ:XENE) have trended positive on Saturday, Accern Sentiment reports. The research firm identifies positive and negative press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Xenon Pharmaceuticals earned a news impact score of 0.26 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 46.0426541852531 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

XENE has been the subject of several research analyst reports. Canaccord Genuity restated a “buy” rating and set a $5.00 price target on shares of Xenon Pharmaceuticals in a research report on Tuesday, June 27th. Jefferies Group LLC set a $5.00 price objective on shares of Xenon Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, August 4th. Finally, Zacks Investment Research raised shares of Xenon Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, September 21st. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $10.63.

Shares of Xenon Pharmaceuticals (NASDAQ XENE) traded up 1.69% during mid-day trading on Friday, reaching $3.00. 51,045 shares of the company traded hands. Xenon Pharmaceuticals has a 52 week low of $2.25 and a 52 week high of $9.95. The stock’s 50-day moving average is $3.04 and its 200-day moving average is $3.64. The company’s market capitalization is $53.99 million.

Xenon Pharmaceuticals (NASDAQ:XENE) last posted its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.03). The firm had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.38 million. Xenon Pharmaceuticals had a negative net margin of 3,489.63% and a negative return on equity of 47.53%. On average, equities analysts predict that Xenon Pharmaceuticals will post ($0.97) EPS for the current fiscal year.

In related news, insider Value Fund L. P. Biotechnology bought 60,202 shares of the stock in a transaction that occurred on Tuesday, August 15th. The stock was purchased at an average cost of $2.61 per share, for a total transaction of $157,127.22. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Bvf Partners L. P/Il bought 41,344 shares of the stock in a transaction that occurred on Monday, August 14th. The stock was bought at an average price of $2.70 per share, with a total value of $111,628.80. The disclosure for this purchase can be found here. In the last three months, insiders bought 210,739 shares of company stock valued at $568,975. Company insiders own 9.40% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece of content was first published by Transcript Daily and is the property of of Transcript Daily. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this piece of content can be viewed at https://transcriptdaily.com/2017/10/08/favorable-press-coverage-somewhat-unlikely-to-impact-xenon-pharmaceuticals-xene-share-price.html.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes: Glybera, TV-45070, GDC-0310, XEN901 (Nav1.6 inhibitor) and XEN1101. Glybera is used for the treatment of lipoprotein lipase deficiency (LPLD).

Insider Buying and Selling by Quarter for Xenon Pharmaceuticals (NASDAQ:XENE)

Receive News & Ratings for Xenon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply